Therefore, we evaluated the mechanisms and relative efficacy of PLK1 inhibition in the context of TMZ and/or XRT treatments in GBM cell lines in-vitro and the synergistic effect of volasertib and TMZ in-vivo. The gene discussed is PLK1; the disease is glioblastoma.